THOMAS KANG: Open Payments
NPI 1730886839 · DULUTH, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$830 in 37 payments from 18 companies in 2025. Trend: 2023 $620 · 2024 $948 · 2025 $830
Food & beverage: $830
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $158 |
| GlaxoSmithKline, LLC. | 5 | $100 |
| Lundbeck LLC | 3 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| Lilly USA, LLC | 2 | $46 |
| ABBVIE INC. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| Boston Scientific Corporation | 2 | $39 |
| Astellas Pharma US Inc | 2 | $37 |
Products named: REXULTI, NUZYRA, CAPLYTA, TRELEGY ELLIPTA, WATCHMAN Access System, AREXVY, Veozah, VRAYLAR.
Industry payments across GA — which companies pay providers there.
